Amicus therapeutics, inc. (FOLD)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13Jun'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Revenue:
Net product sales

208,716

182,237

159,588

131,416

108,595

91,245

73,330

63,608

49,457

36,930

24,328

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold

24,460

21,963

19,362

18,076

15,844

14,404

12,670

10,150

8,076

6,236

3,970

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,224

1,263

0

0

0

-

11,591

15,561

19,699

16,602

14,794

0

0

0

Collaboration and milestone revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,820

8,480

10,140

6,640

6,640

0

0

0

Total revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,224

1,263

0

0

0

-

18,411

24,041

29,839

23,242

21,434

0

0

0

Gross profit

184,256

160,274

140,226

113,340

92,751

76,841

60,660

53,458

41,381

30,694

20,358

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Research and development

310,905

286,378

251,683

331,018

294,697

270,902

259,493

161,907

159,232

149,310

134,132

125,948

112,244

104,793

96,788

85,302

84,255

76,943

69,923

61,001

53,745

47,624

42,129

40,805

0

0

0

50,273

53,628

55,840

53,735

50,856

0

0

0

Selling, general, and administrative

165,773

169,861

165,326

157,513

144,107

127,200

117,016

106,796

96,935

88,671

78,771

74,593

74,582

71,151

69,662

67,565

56,543

47,269

35,595

25,493

21,968

20,717

19,834

19,394

0

0

0

19,364

18,826

18,672

19,573

19,880

0

0

0

Changes in fair value of contingent consideration payable

-2,845

-3,297

-3,252

-3,763

-3,583

-3,300

-7,000

238,550

237,800

234,322

241,090

950

-8,186

-6,760

-11,205

-16,615

-6,529

-4,377

-3,300

-1,400

-1,605

-100

0

0

0

-

-

-

-

-

-

-

-

-

-

Loss on impairment of assets

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

5,548

4,775

4,462

4,419

4,238

4,216

4,122

3,900

3,739

3,593

3,392

3,437

3,392

3,242

2,913

2,412

1,998

1,833

1,620

1,600

1,643

1,547

1,612

1,687

0

0

0

1,705

1,625

1,583

1,567

1,585

0

0

0

Total operating expenses

485,071

464,311

424,723

496,713

446,625

405,618

387,631

499,480

487,533

472,679

440,632

203,039

198,423

186,015

179,657

170,979

149,380

130,437

111,044

90,108

77,906

69,925

63,101

61,997

0

0

0

71,342

74,079

76,095

74,875

72,321

0

0

0

Loss from operations

-300,815

-304,037

-284,497

-383,373

-353,874

-328,777

-326,971

-446,022

-446,152

-441,985

-419,715

-189,423

-190,904

-181,890

-177,874

-170,979

-149,380

-130,437

-111,044

-89,815

-77,138

-68,701

-61,838

-61,027

0

0

0

-52,931

-50,038

-46,256

-51,633

-50,887

0

0

0

Other income (expense):
Interest income

9,125

10,249

11,080

11,049

11,363

10,461

8,765

7,234

5,074

4,096

3,206

2,476

2,054

1,602

1,382

1,238

1,065

929

735

474

352

223

169

160

0

0

0

316

259

198

128

160

0

0

0

Interest expense

16,147

18,872

23,744

24,433

24,368

22,402

18,183

17,819

17,438

17,240

14,701

11,867

8,743

5,398

4,368

2,868

2,151

1,578

1,105

1,465

1,501

1,484

1,113

745

0

0

0

89

104

117

143

148

0

0

0

Restructuring charges

-

-

-

-

-

-

-

-

-

-

-

-

-

69

41

37

55

15

54

62

-45

-63

0

0

0

-

-

-

-

-

-

-

-

-

-

Loss on exchange of convertible notes

-4,500

-40,600

-40,600

-40,600

-36,100

0

0

0

0

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivatives

-

-

-39

-39

-

-2,739

-2,700

-2,700

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-653

1,199

-1,624

-3,820

-2,764

0

0

0

Other (expense) income

-12,028

-2,626

-5,313

-2,871

-7,310

-5,632

-2,637

446

8,162

6,008

3,460

506

-4,131

-4,793

-3,186

-2,330

-103

-80

-140

-97

-97

-77

0

0

0

-

-

-

-

0

-

70

0

0

0

Loss before income tax

-324,366

-355,910

-343,098

-440,252

-417,912

-349,089

-341,765

-458,900

-445,493

-449,121

-441,052

-211,610

-215,026

-203,781

-179,901

-160,127

0

-

0

0

-

-

-

-

-

-

-

-52,030

-51,061

-44,530

-47,828

-48,041

0

0

0

Income tax expense

671

478

1,644

1,844

1,466

-94

-1,645

-166,277

-166,567

-165,119

-164,831

-601

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common stockholders

-325,037

-356,388

-344,742

-442,096

-419,378

-348,995

-340,120

-292,623

-278,926

-284,002

-273,441

-208,429

-211,343

-200,042

-184,292

-175,438

-151,521

-132,118

-110,441

-89,790

-77,271

-68,926

-62,295

-60,495

0

0

0

-48,785

-47,432

-40,901

-44,199

-44,412

0

0

0

Net loss attributable to common stockholders per common share - basic and diluted (in dollars per share)

-0.35

-0.32

-0.24

-0.36

-0.56

-0.43

-0.84

-0.33

-0.28

-0.43

-0.69

-0.34

-0.39

-0.41

-0.33

-0.40

-0.35

-0.36

-0.32

-0.27

-0.25

-0.24

-0.22

-0.22

-0.25

-0.29

-0.31

-0.19

-0.33

-0.20

-0.35

-0.24

-0.28

-0.37

-0.39

Weighted-average common shares outstanding - basic and diluted (in shares)

256,968

255,400

254,674

238,089

213,519

189,398

189,162

188,621

175,977

166,852

160,796

143,000

142,770

142,649

140,656

129,122

125,178

125,232

118,724

99,994

95,743

87,320

78,889

67,212

64,353

49,621

49,621

49,493

48,010

46,870

37,887

34,269

34,979

34,530

34,498